CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders

Journal of Neuroimmunology

Volumn 266, Issue 1-2, 2014, Pages 75-81

  Pranzatelli, Michael R ^a   Tate, Elizabeth D ^a   McGee, Nathan R ^a   Verhulst, Steven J ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neuroblastoma; Neurofilament pediatric ranges; Opsoclonus myoclonus syndrome; Paraneoplastic syndrome; Pediatric neuroinflammation

Indexed keywords

BIOLOGICAL MARKER; CORTICOTROPIN; CYTOSKELETON PROTEIN; IMMUNOGLOBULIN; NESTIN; NEUROFILAMENT HEAVY CHAIN PROTEIN; NEUROFILAMENT LIGHT CHAIN PROTEIN; NEURON SPECIFIC ENOLASE; PROTEIN S100B; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOSIS; BIOCHEMISTRY; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOTHERAPY; INFANT; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM INFLAMMATION; OPSOCLONUS MYOCLONUS SYNDROME; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 84891496911     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.11.004     Document Type: Article

References (38)

1. Banik N.L., Matzelle D.C., Gantt-Wilford G., Osborne A., Hogan E.L. Increased calpain content and progressive degradation of neurofilament protein in spinal cord injury. Brain Res. 1997, 752:301-306.
2. Barry D.M., Millecamps S., Julien J.P., Garcia M.L. New movements in neurofilament transport, turnover and disease. Exp. Cell Res. 2007, 313:2110-2120.
3. Clerico A., Tenore A., Bartolozzi S., Remotti D., Ruco L., Domonici C., Properzi E., Castello M.A. Adrenocorticotropic hormone-secreting ganglioneuroblastoma associated with opsomyoclonic encephalopathy: a case report with immunohistochemical study. Med. Pediatr. Oncol. 1993, 21:690-694.
4. Constantinescu R., Rosengren L., Johnels B., Zetterberg H., Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders. Parkinsonism Relat. Disord. 2010, 16:142-145.
5. Giovannoni G. Multiple sclerosis cerebrospinal fluid biomarkers. Dis. Markers 2006, 22:187-196.
6. Grigelioniené G., Blennow M., Török C., Fried G., Dahlin I., Lendahl U., Lagercrantz H. Cerebrospinal fluid of newborn infants contains a deglycosylated form of the intermediate filament nestin. Pediatr. Res. 1996, 40:809-814.
7. Gunnarsson M., Malmeström C., Axelsson M., Sundström P., Dahle C., Vrethem M., Olsson T., Piehl F., Norgren N., Rosengren L., Svenningsson A., Lycke J. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann. Neurol. 2011, 69:83-89.
8. Hu Y.Y., He S.S., Wang X.C., Duan Q.H., Khatoon S., Igbal K., Grunde-Igbal I., Wang J.Z. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci. Lett. 2002, 320:156-160.
9. Huizinga R., van der Star B.J., Kipp M., Jong R., Gerritsen W., Clarner T., Puentes F., Dijkstra C.D., van der Valk P., Amor S. Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis. Glia 2012, 60:422-431.
10. Khalil M., Enzinger C., Langkammer C., Ropele S., Mader A., Trentini A., Vane M.L., Wallner-Blazek M., Bachmaier G., Archelos J.J., Koel-Simmelink M.J., Blankenstein M.A., Fuchs S., Fazekas F., Teunissen C.E. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult. Scler. 2012, 19:436-442.
11. Kuhle J., Plattner K., Bestwick J.P., Lindberg R.L., Ramagopalan S.V., Norgren N., Nissim A., Malaspina A., Leppert D., Giovannoni G., Kappos L. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult. Scler. 2013, (Mar 25 Epub ahead of print).
12. Liem R.K., Messing A. Dysfunctions of neuronal and glial intermediate filaments in disease. J. Clin. Invest. 2009, 119:1814-1824.
13. Matsushige T., Ichiyama T., Anlar B., Tohyama J., Nomura K., Yamashita Y., Furukawa S. CSF neurofilament and soluble TNF receptor 1 levels in subacute sclerosing panencephalitis. J. Neuroimmunol. 2008, 205:155-159.
14. Matsushige T., Ichiyama T., Kajimoto M., Okuda M., Fukunaga S., Furukawa S. Serial cerebrospinal fluid neurofilament concentrations in bacterial meningitis. J. Neurol. Sci. 2009, 280:59-61.
15. Mellgren A., Price R.W., Hagberg L., Rosengren L., Brew B.J., Gisslén M. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology 2007, 69:1536-1541.
16. Misu T., Takano R., Fujihara K., Takahashi T., Sato S., Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillary acidic protein in neuromyelitis optica: an astrocytic damage marker. J. Neurol. Neurosurg. Psychiatry 2009, 80:575-577.
17. Norgren N., Rosengren L., Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003, 987:25-31.
18. Norgren N., Sundstrom P., Svenningsson A., Rosengren L., Stigbrand T., Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004, 63:1586-1590.
19. Perrot R., Berges R., Bocquet A., Eyer J. Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol. Neurobiol. 2008, 38:27-65.
20. Petzold A., Groves M., Leis A.A., Scaravilli F., Stokic D.S. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile virus infection. Muscle Nerve 2010, 41:42-49.
21. Pleines U.E., Morganti-Kossmann M.C., Rancan M., Joller H., Trentz O., Kossmann T. S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J. Neurotrauma 2001, 18:491-498.
22. Pranzatelli M.R., Tate E.D. Opsoclonus-myoclonus syndrome. Inflammatory and Autoimmune Disorders of the Nervous System in Children 2010, 152-173. Mac Keith Press (Cambridge University Press), United Kingdom. C.D. Russell, A. Vincent (Eds.).
23. Pranzatelli M.R., Tate E.D., Wheeler A., Bass N., Gold A.P., Griebel M.L., Gumbinas M., Heydemann P.T., Holt P.J., Jacob P., Kotagal S., Minarcik C.J., Schub H.S. Screening for autoantibodies in children with opsoclonus-myoclonus ataxia. Pediatr. Neurol. 2002, 27:384-387.
24. Pranzatelli M.R., Travelstead A.L., Tate E.D., Allison T.J., Moticka E.J., Franz D.N., Nigro M.A., Parke J.T., Stumpf D.A., Verhulst S.J. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004, 62:1526-1532.
25. Pranzatelli M.R., Tate E.D., Swan J.A., Travelstead A.L., Colliver J.A., Verhulst S.J., Crosley C.J., Graf W.D., Joseph S.A., Kelfer H.M., Raju G.P. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov. Disord. 2010, 25:238-242.
26. Pranzatelli M.R., Slev P.R., Tate E.D., Travelstead A.L., Colliver J.A., Joseph S.A. Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus. Pediatr. Neurol. 2011, 45:27-33.
27. Pranzatelli M.R., Tate E.D., McGee N.R., Travelstead A.L., Ransohoff R.M., Ness J.M., Colliver J.A. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS. J. Neuroimmunol. 2012, 243:81-88.
28. Pranzatelli M.R., Tate E.D., McGee N.R., Colliver J.A., Ransohoff R.M. CCR4 agonists CCL22 and CCL17 are elevated in pediatric OMS sera: rapid and selective down-regulation of CCL22 by ACTH or corticosteroids. J. Clin. Immunol. 2013, 33:817-825.
29. Pranzatelli M.R., Tate E.D., McGee N.R., Travelstead A.L., Colliver J.A., Ness J.M., Ransohoff R.M. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy. J. Neuroinflammation 2013, 10:10. (Jan 16). 10.1186/1742-2094-10-10.
30. Rao M.V., Yuan A., Campbell J., Kumar A., Nixon R.A. The C-terminal domains of NF-H and NF-M subunits maintain axonal neurofilament content by blocking turnover of the stationary neurofilament network. PLoS ONE 2012, 7:e44320. 10.1371/journal.pone.0044320.
31. Salzer J., Svenningsson A., Sundström P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult. Scler. 2010, 16:287-292.
32. Shaw G., Yang C., Ellis R., Anderson K., Parker Mickle J., Scheff S., Pike B., Anderson D.K., Howland D.R. Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem. Biophys. Res. Commun. 2005, 336:1268-1277.
33. Singh P., Yan J., Hull R., Read S., O'Sullivan J., Henderson R.D., Rose S., Greer J.M., McCombe P.A. Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke. J. Neurol. Sci. 2011, 304:117-121.
34. Tate E.D., Pranzatelli M.R., Verhulst S.J., Markwell S.J., Franz D.N., Graf W.D., Joseph S.A., Khakoo Y.N., Lo W.D., Mitchell W.G., Sivaswamy L. Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. J. Child Neurol. 2012, 27:875-884.
35. Teunissen C.E., Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult. Scler. 2012, 18:552-556.
36. Trysberg E., Nylen K., Rosengren L.E., Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003, 48:2881-2887.
37. Tuchman R.F., Alvarez L.A., Kantrowitz A.B., Moser F.G., Llena J., Moshé S.L. Opsoclonus-myoclonus syndrome: correlation of radiographic and pathologic observations. Neuroradiology 1989, 31:250-252.
38. Ziter F.A., Bray P.F., Cancilla P.A. Neuropathological findings in a patient with neuroblastoma and myoclonic encephalopathy. Arch. Neurol. 1979, 36:51.